| John R Savoy, | |
|
1541 Kings Hwy, Shreveport, LA 71103-4228 | |
| (318) 813-2655 | |
| Not Available |
| Full Name | John R Savoy |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 8 Years |
| Location | 1541 Kings Hwy, Shreveport, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235592601 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 327905 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Lsu Health Shreveport | Shreveport, LA | Hospital |
| Ochsner Lsu Health Shreveport-st Mary Medical Cent | Shreveport, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lsu Health Sciences Center Shreveport Faculty Group Practice | 4082902721 | 529 |
News Archive
Genetic research aimed at improving healthcare will be the focus of the University of Queensland's new Genome Innovation Hub.
Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection.
Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
Minimum pricing for alcohol of 45p per unit would reduce deaths and hospital admissions among high risk drinkers who purchase large quantities of low cost alcohol, but would have negligible effects on low income moderate drinkers' alcohol consumption and spending, according to a new modelling study from the University of Sheffield, UK, published in The Lancet.
› Verified 7 days ago
| Entity Name | Lsu Health Sciences Center Shreveport Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013374222 PECOS PAC ID: 4082902721 Enrollment ID: O20161012000307 |
News Archive
Genetic research aimed at improving healthcare will be the focus of the University of Queensland's new Genome Innovation Hub.
Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection.
Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
Minimum pricing for alcohol of 45p per unit would reduce deaths and hospital admissions among high risk drinkers who purchase large quantities of low cost alcohol, but would have negligible effects on low income moderate drinkers' alcohol consumption and spending, according to a new modelling study from the University of Sheffield, UK, published in The Lancet.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John R Savoy, 1512 W Kirby Pl, Shreveport, LA 71103-3822 Ph: () - | John R Savoy, 1541 Kings Hwy, Shreveport, LA 71103-4228 Ph: (318) 813-2655 |
News Archive
Genetic research aimed at improving healthcare will be the focus of the University of Queensland's new Genome Innovation Hub.
Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection.
Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
Minimum pricing for alcohol of 45p per unit would reduce deaths and hospital admissions among high risk drinkers who purchase large quantities of low cost alcohol, but would have negligible effects on low income moderate drinkers' alcohol consumption and spending, according to a new modelling study from the University of Sheffield, UK, published in The Lancet.
› Verified 7 days ago
James R Barnes, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1455 E Bert Koun Loop, Suite #105, Shreveport, LA 71105 Phone: 318-798-4433 Fax: 318-798-4432 | |
Mary T Kim, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1501 Kings Hwy, Shreveport, LA 71103 Phone: 318-675-6154 | |
Dr. Paul E Perkowski, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1541 Kings Hwy, Shreveport, LA 71103 Phone: 318-626-0000 Fax: 318-629-4833 | |
Dr. James Booth Burke, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1202 Louisiana Avenue, Shreveport, LA 71101 Phone: 318-212-8780 Fax: 318-212-6752 | |
Jennifer Kim, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1501 Kings Hwy, Surgery, Shreveport, LA 71103 Phone: 318-675-2655 | |
Dr. Terry Lairmore, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1541 Kings Hwy, Shreveport, LA 71103 Phone: 318-626-0000 | |
Dr. Mark H Smith, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2751 Albert L Bicknell Dr, Suite 3d, Shreveport, LA 71103 Phone: 318-212-4799 Fax: 318-424-3642 |